CMPX Stock Overview
A clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Compass Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.71 |
| 52 Week High | US$2.34 |
| 52 Week Low | US$0.77 |
| Beta | 0.71 |
| 11 Month Change | 35.71% |
| 3 Month Change | 61.32% |
| 1 Year Change | -14.07% |
| 33 Year Change | -51.14% |
| 5 Year Change | n/a |
| Change since IPO | -79.88% |
Recent News & Updates
Recent updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial
Oct 11Shareholder Returns
| CMPX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.0% | -1.3% | 1.2% |
| 1Y | -14.1% | 23.2% | 30.2% |
Return vs Industry: CMPX underperformed the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: CMPX underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| CMPX volatility | |
|---|---|
| CMPX Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CMPX's share price has been volatile over the past 3 months.
Volatility Over Time: CMPX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 32 | Tom Schuetz | www.compasstherapeutics.com |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.
Compass Therapeutics, Inc. Fundamentals Summary
| CMPX fundamental statistics | |
|---|---|
| Market cap | US$218.77m |
| Earnings (TTM) | -US$47.24m |
| Revenue (TTM) | US$850.00k |
276.8x
P/S Ratio-5.0x
P/E RatioIs CMPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMPX income statement (TTM) | |
|---|---|
| Revenue | US$850.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$850.00k |
| Other Expenses | US$48.09m |
| Earnings | -US$47.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,557.88% |
| Debt/Equity Ratio | 0% |
How did CMPX perform over the long term?
See historical performance and comparison